OncoMatch/Clinical Trials/NCT05027633
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
Is NCT05027633 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Docetaxel for squamous cell carcinoma.
Treatment: Pembrolizumab · Docetaxel · Cisplatin · Carboplatin — This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell carcinoma of the nasal cavity/paranasal sinuses (PNS SCC).
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage II, III, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
Cannot have received: systemic anti-cancer therapy
Exception: could have received treatment for prior cancers if greater than 2 years
Patients must not have received prior systemic anti-cancer therapy including investigational agents or radiation therapy for PNS SCC but could have received treatment for prior cancers if greater than 2 years
Cannot have received: radiation therapy
Exception: could have received treatment for prior cancers if greater than 2 years
Patients must not have received prior systemic anti-cancer therapy including investigational agents or radiation therapy for PNS SCC but could have received treatment for prior cancers if greater than 2 years
Lab requirements
Blood counts
adequate organ function as defined in the following table (Table 1)
Kidney function
adequate organ function as defined in the following table (Table 1)
Liver function
adequate organ function as defined in the following table (Table 1)
adequate organ function as defined in the following table (Table 1). Blood must be collected within 14 days prior to the start of study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify